Xiao Yao, Xiao Li, Zhang Yang, Xu Ximing, Guan Xianmin, Guo Yuxia, Shen Yali, Lei XiaoYing, Dou Ying, Yu Jie
Department of Hematology and Oncology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
College of Medical Informatics, Chongqing Medical University, Chongqing, China.
Front Oncol. 2024 Mar 7;14:1337295. doi: 10.3389/fonc.2024.1337295. eCollection 2024.
Tumor lysis syndrome (TLS) often occurs early after induction chemotherapy for acute lymphoblastic leukemia (ALL) and can rapidly progress. This study aimed to construct a machine learning model to predict the risk of TLS using clinical indicators at the time of ALL diagnosis.
This observational cohort study was conducted at the National Clinical Research Center for Child Health and Disease. Data were collected from pediatric ALL patients diagnosed between December 2008 and December 2021. Four machine learning models were constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) to select key clinical indicators for model construction.
The study included 2,243 pediatric ALL patients, and the occurrence of TLS was 8.87%. A total of 33 indicators with missing values ≤30% were collected, and 12 risk factors were selected through LASSO regression analysis. The CatBoost model with the best performance after feature screening was selected to predict the TLS of ALL patients. The CatBoost model had an AUC of 0.832 and an accuracy of 0.758. The risk factors most associated with TLS were the absence of potassium, phosphorus, aspartate transaminase (AST), white blood cell count (WBC), and urea levels.
We developed the first TLS prediction model for pediatric ALL to assist clinicians in risk stratification at diagnosis and in developing personalized treatment protocols. This study is registered on the China Clinical Trials Registry platform (ChiCTR2200060616).
https://www.chictr.org.cn/, identifier ChiCTR2200060616.
肿瘤溶解综合征(TLS)常发生于急性淋巴细胞白血病(ALL)诱导化疗后的早期,且病情可迅速进展。本研究旨在构建一种机器学习模型,利用ALL诊断时的临床指标预测TLS风险。
本观察性队列研究在国家儿童健康与疾病临床研究中心开展。收集了2008年12月至2021年12月期间诊断的儿科ALL患者的数据。使用最小绝对收缩和选择算子(LASSO)构建了四个机器学习模型,以选择用于模型构建的关键临床指标。
该研究纳入了2243例儿科ALL患者,TLS的发生率为8.87%。共收集了缺失值≤30%的33项指标,并通过LASSO回归分析选择了12个危险因素。选择特征筛选后性能最佳的CatBoost模型来预测ALL患者的TLS。CatBoost模型的AUC为0.832,准确率为0.758。与TLS最相关 的危险因素是血钾、血磷、天冬氨酸转氨酶(AST)、白细胞计数(WBC)和尿素水平的缺乏。
我们开发了首个用于儿科ALL的TLS预测模型,以协助临床医生在诊断时进行风险分层并制定个性化治疗方案。本研究已在中国临床试验注册平台注册(ChiCTR2200060616)。